Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMEGON vs DANAZOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.
Induction of ovulation in women with oligomenorrhea or anovulation not due to primary ovarian failure,Stimulation of multiple follicle development in ovulatory women participating in assisted reproductive technology (ART) programs,Induction of spermatogenesis in men with hypogonadotropic hypogonadism (in combination with h CG)
FDA: Treatment of endometriosis, fibrocystic breast disease, hereditary angioedema,Off-label: Idiopathic thrombocytopenic purpura, precocious puberty, gynecomastia
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
300-600 mg orally twice daily; maximum 800 mg/day
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Terminal elimination half-life is 4-4.5 hours; clinical context: requires multiple daily dosing to maintain therapeutic levels.
The metabolic pathway of menotropins is not fully characterized; however, it is likely degraded via proteolysis into smaller peptides and amino acids in the liver and kidneys.
Primarily hepatic: undergoes oxidation and conjugation via CYP3A4, with metabolites excreted in urine and feces.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Primarily hepatic metabolism; approximately 60% excreted in feces, 30% in urine as metabolites.
Approximately 30-40% bound to serum albumin; no specific binding proteins identified.
Highly protein bound: 97-99%, primarily to albumin.
Approximately 0.3-0.5 L/kg (total body water); indicates distribution primarily into extracellular fluid.
Approximately 1.5 L/kg; indicates extensive distribution into tissues, exceeding total body water.
IM/SC: Approximately 80-90% absolute bioavailability (due to first-pass hepatic metabolism with oral route being ineffective).
Oral bioavailability is approximately 100% due to extensive absorption, but first-pass metabolism reduces systemic availability to about 70-80%.
No specific dose adjustment guidelines; use caution in severe renal impairment.
No adjustment required for GFR ≥10 m L/min; avoid use in GFR <10 m L/min due to fluid retention risk
No specific dose adjustment guidelines; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Not indicated for use in pediatric patients.
2-5 mg/kg/dose orally twice daily; maximum 400 mg/day
Not indicated for use in geriatric patients.
Start at low end of adult dose, titrate cautiously due to increased risk of fluid retention and thromboembolism
HUMEGON should only be used by physicians who are experienced in infertility treatment and familiar with the potential risks. The drug has been associated with serious pulmonary and vascular events, including thromboembolism, ovarian hyperstimulation syndrome (OHSS), and multiple pregnancies. Female patients should be advised of the risk of OHSS and multiple gestations.
Danazol may cause thrombotic events, including pulmonary embolism and thrombophlebitis. It is contraindicated in patients with a history of thrombosis.
Risk of Ovarian Hyperstimulation Syndrome (OHSS): may progress to severe form with ascites, pleural effusion, oliguria, and thromboembolic events.,Thromboembolic events: increased risk especially in patients with predisposing factors.,Ovarian torsion: reported in post-treatment period.,Multiple pregnancies: high incidence, especially with higher doses.,Ovarian enlargement: may be asymptomatic or cause abdominal pain.,Ectopic pregnancy: increased risk in patients with tubal disease.,Congenital malformations: incidence may be slightly higher than spontaneous pregnancies.,Monitoring: requires ultrasound and estradiol levels to minimize risks.
Hepatotoxicity (monitor LFTs), pseudotumor cerebri (benign intracranial hypertension), androgenic effects (hirsutism, acne, voice deepening), lipid changes (decreased HDL, increased LDL), thromboembolic events, and premature closure of epiphyses in children.
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Pituitary tumor,Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement not due to polycystic ovary syndrome (PCOS),Sex hormone-dependent tumors (e.g., breast, uterus, ovary, prostate),Pregnancy,Hypersensitivity to menotropins or any component
Pregnancy, lactation, porphyria, severe hepatic/renal/cardiac disease, undiagnosed abnormal genital bleeding, history of thromboembolic disorders, androgen-dependent tumors.
No specific food interactions documented. Maintain a balanced diet; no restrictions necessary.
Take with food or milk to minimize gastrointestinal irritation. Avoid grapefruit juice as it may alter drug metabolism. Limit alcohol consumption due to increased risk of hepatotoxicity.
HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic effects have been reported from inadvertent exposure during early pregnancy, but fetal risks include increased incidence of multiple births and associated prematurity, low birth weight, and perinatal morbidity. Avoid use during pregnancy.
Danazol is contraindicated in pregnancy. First trimester exposure is associated with virilization of female fetus including clitoromegaly, labioscrotal fusion, and urogenital sinus abnormalities. Risk in second and third trimesters is also significant due to androgenic effects; fetal growth restriction and preterm birth may occur. No safe gestational period exists.
It is not known whether menotropins are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. No M/P ratio is available.
Danazol is excreted in human milk; M/P ratio not determined. Potential for adverse effects in breastfed infant (e.g., androgenization). Use is contraindicated during breastfeeding due to risk of virilization and other hormonal effects.
HUMEGON is contraindicated during pregnancy. No dosing adjustments in pregnancy are applicable as it is not used during pregnancy.
Danazol is contraindicated in pregnancy; no dose adjustment recommendations exist. If inadvertently used during pregnancy, discontinue immediately and monitor for fetal effects. Pharmacokinetic changes in pregnancy are not studied; dose modifications are not applicable due to contraindication.
Humegon (menotropins) contains FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize OHSS risk. Administer IM or SC; reconstitute with provided diluent and use immediately. Avoid in primary ovarian failure. Combine with h CG for final oocyte maturation.
Monitor liver function tests; androgenic effects (acne, hirsutism, voice deepening) may occur; use with caution in patients with cardiac or renal impairment; may potentiate warfarin; effective for hereditary angioedema prophylaxis; check pregnancy test before initiation due to teratogenicity.
Inject exactly as prescribed; do not miss doses.,Report abdominal pain, bloating, nausea, or rapid weight gain immediately (OHSS signs).,Multiple pregnancy is possible; discuss risks.,Store unopened vials in refrigerator; use reconstituted solution promptly.,Avoid alcohol and smoking during treatment.,Inform doctor of all medications, including herbal supplements.
Do not take if pregnant or planning pregnancy; use effective contraception.,Report symptoms of liver toxicity (jaundice, dark urine, abdominal pain) immediately.,Avoid alcohol as it may increase hepatotoxicity risk.,May cause weight gain, acne, or voice changes; report if bothersome.,Take with food to reduce GI upset.,Use sunscreen due to photosensitivity risk.,Do not discontinue abruptly; taper under medical supervision.
No interactions on record
"Formestane, an aromatase inhibitor, reduces estrogen synthesis, while danazol, a synthetic androgen, possesses weak androgenic and anabolic activity. Concomitant use may lead to additive fluid retention due to danazol's mineralocorticoid-like effects and formestane's potential to cause fluid retention through estrogen withdrawal. This can result in peripheral edema, hypertension, or exacerbation of heart failure in susceptible patients."
"Danazol, a synthetic androgen with weak androgenic activity, may reduce the therapeutic efficacy of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used for glycemic control in type 2 diabetes. The proposed mechanism involves danazol-induced activation of cytochrome P450 enzymes (particularly CYP3A4) and potential upregulation of glucagon counter-regulatory pathways, leading to increased vildagliptin clearance and diminished inhibition of DPP-4. Clinically, this interaction may result in elevated postprandial glucose levels and reduced HbA1c reduction, compromising glycemic management."
"Danazol, an androgenic steroid, can induce hepatic microsomal enzymes, particularly CYP2C9, which accelerates the metabolism of glipizide, a sulfonylurea antidiabetic agent. This increased clearance reduces glipizide's plasma concentrations, diminishing its insulinotropic effect and potentially leading to hyperglycemia and loss of glycemic control in patients with type 2 diabetes mellitus."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMEGON vs DANAZOL, answered by our medical review team.
HUMEGON is a Gonadotropin that works by HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.. DANAZOL is a Androgen/Antigonadotropin that works by Danazol is a synthetic androgen derived from ethisterone that suppresses pituitary-ovarian axis by inhibiting gonadotropin release, leading to decreased estrogen and progesterone levels. It also has weak androgenic and progestational activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMEGON and DANAZOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMEGON is: 75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.. The standard adult dose of DANAZOL is: 300-600 mg orally twice daily; maximum 800 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMEGON and DANAZOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMEGON is classified as Category C. HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic. DANAZOL is classified as Category C. Danazol is contraindicated in pregnancy. First trimester exposure is associated with virilization of female fetus including clitoromegaly, labioscrotal fusion, and urogenital sinus. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.